TCTMD

Aquapass: Non-Invasive Treatment for Fluid Overload in Chronic Heart Failure Patients

Within the last 24 months, I have financial relationship(s) or affiliation(s) with a manufacturer, marketer, reseller, or distributor of a healthcare product or service involved in the management of ...
Morningstar

AQUAPASS Receives Marketing Approval in Israel, Enabling Access to Novel Therapy for Patients with Fluid Overload

NEWTON, Mass. and SHEFAYIM, Israel, Dec. 8, 2025 /PRNewswire/ -- AQUAPASS, a medical technology company pioneering non-invasive fluid management solutions, has received marketing approval for the ...
Nasdaq

Nuwellis Receives Increased Reimbursement Rate for Aquadex SmartFlow® Therapy from the Centers for Medicare and Medicaid

MINNEAPOLIS, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage medical device company committed to transforming the lives of people with fluid overload, is pleased to ...
Business Wire

Reprieve Cardiovascular Emerges from Stealth Mode after $42 Million Series A Financing to Bring Intelligent Fluid Management to Heart Failure Patients

MILFORD, Mass.--(BUSINESS WIRE)--Reprieve Cardiovascular, Inc., a development stage company focused on pioneering an intelligent automated diuretic and fluid management approach for acute ...
Healio

Speaker: Fluid overload greater than 10% of body weight correlates with AKI, mortality

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. BOSTON — Several studies indicate that fluid overload ...
Nasdaq

Nuwellis, Inc. Terminates REVERSE-HF Clinical Trial to Focus on Outpatient Market Opportunities

Nuwellis, Inc. has announced the termination of its REVERSE-HF clinical trial, which was evaluating the use of ultrafiltration versus IV loop diuretics for managing fluid in heart failure patients.